RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 ENGAGE AF-TIMI 48: Tailoring Edoxaban Dose Preserves Drug Efficacy and Safety
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 27
SP 25
OP 27
DO 10.1177/155989771427016
UL http://mdc.sagepub.com/content/14/27/25.abstract
AB The Effective Anticoagulation With Factor Xa Next Generation in the Atrial Fibrillation—TIMI 48 trial [ENGAGE AF-TIMI 48; Giugliano RP et al. N Engl J Med. 2013] of 21?105 patients with atrial fibrillation and CHADS2 scores =?2 reported the noninferiority of the oral factor Xa inhibitor edoxaban 30 and 60 mg once daily versus warfarin and dose-related decreases in major bleeding. This article presents the results of a subanalysis showing that the protocol-driven dose adjustments in ENGAGE AF maintained the efficacy of edoxaban and reduced bleeding.